The experiments described here in MRL/lpr lupus-prone mice aimed at defining the therapeutic potential of PDE4 inhibitors in this autoimmune disease, which is characterized by nephropathy and inflammatory processes. The gene discussed is PDE4A; the disease is systemic lupus erythematosus.